Find News

Filter articles

Applied Filters

Showing 101 to 110 of 133 results

Market for fighting fake pharma packets to soar in value, report says


The global market for products seeking to tackle counterfeit pharmaceutical and cosmetics packaging will reach more than $80 billion by 2020, according to a report.

SIPO rejects Gilead’s Sovaldi patent application


China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.

BIO 2015: Australia may block gene patents, suggests NZ lawyer

Australia, Canada, EU, New Zealand18-06-2015

Australia could be going down the road of no longer allowing gene patents, New Zealand-based patent lawyer David Nowak said at the BIO International Convention yesterday.

Australia’s highest court sets date for Myriad hearing


The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17.

Australia targets reduced drug spending with new reforms


The Australian health minister has revealed a series of reforms that will aim to reduce spending on patented drugs from the pharmaceutical industry.

Gilead faces fresh Sovaldi challenge

Brazil, China, Russia20-05-2015

Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.

AIDS group warns of TPP’s impact on access to generic medicine


The Foundation for AIDS Research has warned that the Trans-Pacific Partnership’s changes to IP policy could restrict access to affordable generic medicines in low and middle income countries.

Otsuka acquires Avanir in $3.5 billion deal

Japan02-12-2014Mergers & acquisitions

Japanese drug maker Otsuka Holdings has agreed to buy Avanir Pharmaceuticals as part of a multi-billion dollar deal that could ease its potential patent woes.

‘Worrying trend’ of Aussie counterfeit pharmaceuticals


Criminal gangs in Australia are branching away from traditional forms of counterfeiting and are targeting pharmaceuticals, an Australian customs official has revealed.

Cipla agrees Rifaximin licensing deal


Indian drug maker Cipla has signed a deal with Salix Pharmaceuticals allowing the US-based company exclusive rights relating to the Rifaximin Complexes patent family.

Showing 101 to 110 of 133 results